Table 1.
Standardised rate ratios of reported and clinically confirmed Bell's palsy cases following vaccination with CoronaVac and BNT162b2
| Age-standardised background incidence in 2020*per 100 000 person-years (95% CI) |
Age-standardised incidence per 100 000 person-years (95% CI) |
Age-standardised incidence difference per 100 000 person-years (95% CI) |
Age-standardised rate ratio (95% CI) |
||||
|---|---|---|---|---|---|---|---|
| Reported | Clinically confirmed | Reported | Clinically confirmed | Reported | Clinically confirmed | ||
| CoronaVac | |||||||
| Total | 25·3 (22·6 to 28·1) | 75·3 (44·7 to 105·9) | 66·9 (37·2 to 96·6) | 49·9 (19·2 to 80·7) | 41·5 (11·7 to 71·4) | 2·97 (1·95 to 4·53) | 2·64 (1·67 to 4·17) |
| Male | 29·0 (24·5 to 33·4) | 88·7 (45·7 to 131·6) | 77·6 (36·1 to 119·2) | 59·7 (16·6 to 102·9) | 48·7 (6·9 to 90·4) | 3·06 (1·84 to 5·09) | 2·68 (1·54 to 4·68) |
| Female | 22·4 (18·9 to 26·0) | 55·9 (15·1 to 96·6) | 51·9 (11·9 to 91·9) | 33·4 (−7·4 to 74·3) | 29·5 (−10·6 to 69·6) | 2·49 (1·18 to 5·25) | 2·31 (1·05 to 5·08) |
| BNT162b2 | |||||||
| Total | 25·7 (22·7 to 28·8) | 57·8 (30·1 to 85·5) | 42·8 (19·4 to 66·1) | 32·1 (4·2 to 59·9) | 17·0 (−6·6 to 40·6) | 2·25 (1·37 to 3·68) | 1·66 (0·95 to 2·91) |
| Male | 28·9 (24·1 to 33·8) | 65·5 (26·9 to 104·2) | 46·1 (14·6 to 77·5) | 36·6 (−2·3 to 75·5) | 17·1 (−14·7 to 49·0) | 2·26 (1·23 to 4·18) | 1·59 (0·79 to 3·22) |
| Female | 23·1 (19·2 to 27·0) | 46·1 (8·7 to 83·5) | 36·4 (4·2 to 68·7) | 23·0 (−14·6 to 60·5) | 13·3 (−19·2 to 45·8) | 1·99 (0·87 to 4·56) | 1·58 (0·64 to 3·88) |
*
The background incidence was calculated using the same reporting period in 2020 as for each vaccination programme in 2021 (for CoronaVac, Feb 23–May 4; for BNT162b2, March 6–May 4).